Egetis Therapeutics AB

As of June 30, 2026, Egetis Therapeutics AB carries a market capitalization of 244.56M, placing it among publicly traded companies globally. Its enterprise value stands at 216.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Egetis Therapeutics AB's next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Egetis Therapeutics AB has 464.95M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 35.21, and the price-to-book ratio stands at 5.63.

These figures are as of June 30, 2026. The EV/Sales ratio of 36.24 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 216.24M versus a market cap of 244.56M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Egetis Therapeutics AB maintains a current ratio of 1.49, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.44, indicating elevated leverage, while an interest coverage ratio of -21.57 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Egetis Therapeutics AB posted a negative return on equity (ROE) of -96.94, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -57.32, reflecting losses generated across the asset base. The company generates approximately 143,799.41 in revenue per employee across its workforce of 41.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 39.29 indicates how many times Egetis Therapeutics AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Egetis Therapeutics AB recorded 36,113.01 in income tax expense. The company reported a pretax loss of -36.57M and -36.61M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 0.74, while the 200-day moving average is 0.57.

Over the twelve months ended June 30, 2026, Egetis Therapeutics AB generated 5.97M in revenue and converted that into -36.61M in net income, yielding earnings per share of -0.09. EBITDA reached -36.02M, while operating income came in at -36.09M.

As of June 30, 2026, Egetis Therapeutics AB holds 34.16M in cash and equivalents against 5.84M in total debt, resulting in a net debt position of -28.32M. Total book value stands at 43.47M, with working capital of 11.74M providing operational flexibility.

Egetis Therapeutics AB produced -27.10M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -90,282.53 in capital expenditures, free cash flow totaled -27.19M - equivalent to -0.07 per share.

Over the twelve months ended June 30, 2026, Egetis Therapeutics AB posted a gross margin of 16.79, reflecting its pricing power and cost economics. The operating margin of -604.69 and net profit margin of -613.46 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -12.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -17.50, meaning Egetis Therapeutics AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Egetis Therapeutics AB's most recent stock split took place on April 27, 2022 with a 89:97 split ratio.

As of June 30, 2026, Egetis Therapeutics AB has an Altman Z-Score of -4.25, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.